Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02982902 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

T Cell Therapy of Opportunistic Cytomegalovirus Infection

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contact updatedv15
  2. Primary completion date: Sep 2024 to Aug 2027
    • Study completion date: Sep 2025 to Aug 2028
    • Site contact updated
    v14
  3. Primary completion date: Mar 2024 to Sep 2024
    • Study completion date: Mar 2025 to Sep 2025
    v13
  4. Primary completion date: Sep 2023 to Mar 2024
    • Study completion date: Sep 2024 to Mar 2025
    v12
  5. Primary completion date: Jan 2023 to Sep 2023
    • Study completion date: Nov 2023 to Sep 2024
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Primary completion date: Jun 2022 to Jan 2023
    • Start date: Dec 2016 to May 27, 2020
    • Study completion date: Nov 2022 to Nov 2023
    v10
  2. Primary completion date: Sep 2021 to Jun 2022
    • Study completion date: Sep 2022 to Nov 2022
    v9
  3. Site contact updatedv8
  4. Lead sponsor: Marcos de Lima to Mari Dallas
    • Primary completion date: Dec 2020 to Sep 2021
    • Study completion date: Dec 2021 to Sep 2022
    • Study site revised
    v7
  5. Primary completion date: Mar 2020 to Dec 2020
    • Study completion date: Mar 2021 to Dec 2021
    v6
  6. Lead sponsor: Case Comprehensive Cancer Center to Marcos de Lima
    • Primary completion date: Mar 2019 to Mar 2020
    • Study completion date: Mar 2020 to Mar 2021
    v5
  7. Primary completion date: Jan 2018 to Mar 2019
    • Study completion date: Jan 2019 to Mar 2020
    v4
  8. Eligibility criteria expanded, about 13 wordsv3
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2017 to Dec 2016
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV. Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).
Trial Details
NCT Number NCT02982902
Lead Sponsor Mari Dallas
Conditions
(from sponsor)		 Cytomegalovirus Infections, Hematopoietic Stem Cell Transplant, Opportunistic Infections
Related terms Cytomegalovirus Infections, Lymphoproliferative Disorders, Opportunistic Infections
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov